Related Experiment Video
Updated: Aug 25, 2026
09:35
Environmental Modulations of the Number of Midbrain Dopamine Neurons in Adult Mice
Published on: January 20, 2015
ZD-6126 AstraZeneca
1Tumor Biology Center, Department of Medical Oncology, Breisacher Strasse 117, 79106 Freiburg, Germany. drevs@tumorbio.uni-freiburg.de
Idrugs : the Investigational Drugs Journal
|April 2, 2004
Abstract:
AstraZeneca is developing ZD-6126, one of the ANG-400 series of vascular-targeting and tubulin-binding agents under license from Angiogene Pharmaceuticals Ltd, for the potential treatment of cancer.
